source
- Overseas MDMA and psilocybin makers eye U.S. market as regulatory landscape easesCompanies that produce MDMA and psilocybin for patients abroad are turning their attention to the United States, hoping to leverage experience gained under more permissive foreign rules. Rising pol…
- Redx Pharma pursues new reverse merger with Skye after 2023 setbackRedx Pharma, a UK biotech focused on ROCK inhibitor therapies for fibrosis, is seeking a reverse merger with Skye to obtain a Nasdaq listing. The company previously attempted a similar transaction…